Affimed 2016 Immuno-Oncology Immune Cell Engagers Corporate Presentation

Affimed presents its clinical and preclinical pipeline of bi- and trispecific antibodies designed to eliminate tumor cells by recruiting NK-cells or T-cells. As a Nasdaq-listed company based in Heidelberg, Germany, Affimed has raised approximately $120 million since September 2014 and operates offices across the U.S. and Czech Republic.